Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE

We agree with the main thrust of the argument in the recent article by Eriksson1 that long-term clopidogrel treatment (8 and 12 months) confers a small, or at most modest, advantage when compared to the standard 1-month treatment in patients undergoing percutaneous coronary intervention.Eriksson should be commended for the critical analysis of the data from PCI-CURE and CREDO. In particular, for pointing out that the small absolute reductions in composite endpoints of death, myocardial infarction, revascularisation in the long-term clopidogrel treatment group compared to the standard 1-month treatment group, could …